OncoMatch/Clinical Trials/NCT07234487
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
Is NCT07234487 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nivo-AVD and BEACOPP-like for hodgkin lymphoma.
Treatment: Nivo-AVD · BEACOPP-like — Patients in this prospective multicenter phase II study will be randomized between two first-line therapy strategies for advanced stages of cHL. In the Nivo-AVD cohort, patients will receive 2 cycles of nivolumab monotherapy followed by a switch to Nivo-AVD combination therapy (total of 6 cycles); in the Standard cohort, patients will receive therapy according to current clinical guidelines in Russian Federation for first-line therapy of cHL, which include starting first-line therapy with 2 cycles of BEACOPP-like regimens and, after assessing response after 2 courses, switching to A(B)VD or continuing with BEACOPP-like regimens
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Disease stage
Required: Stage IIB, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Kidney function
creatinine > 2 norms
Liver function
alanine aminotransferase, aspartate aminotransferase > 5 norms; bilirubin > 1.5 norms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify